Ensysce Biosciences, Inc. Common Stock (ENSC)

Price$0.48

Favorite Metrics

Price vs S&P 500 (26W)-86.52%

Price vs S&P 500 (4W)-23.89%

Market Capitalization$4.49M

All Metrics

Book Value / Share (Quarterly)$0.38

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.86%

Cash Flow / Share (Quarterly)$-2.25

Price vs S&P 500 (YTD)-49.79%

Net Profit Margin (TTM)-244.49%

EPS (TTM)$-6.36

10-Day Avg Trading Volume0.29M

EPS Excl Extra (TTM)$-6.36

EPS (Annual)$-11.45

ROI (Annual)-199.18%

Net Profit Margin (5Y Avg)-768.92%

Cash / Share (Quarterly)$0.53

Revenue Growth QoQ (YoY)-85.58%

ROA (Last FY)-142.62%

Revenue Growth TTM (YoY)1.51%

EBITD / Share (TTM)$-5.67

ROE (5Y Avg)-10.24%

Operating Margin (TTM)-245.89%

Cash Flow / Share (Annual)$-5.52

P/B Ratio3.73x

P/B Ratio (Quarterly)5.85x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)0.71x

Net Interest Coverage (TTM)-5.19x

ROA (TTM)-231.45%

EV / EBITDA (TTM)4.93x

EPS Incl Extra (Annual)$-11.45

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)0.76x

3-Month Avg Trading Volume4.28M

52-Week Price Return-73.40%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)0.86x

Asset Turnover (Annual)0.93x

52-Week High$4.85

Operating Margin (5Y Avg)-887.16%

EPS Excl Extra (Annual)$-11.45

26-Week Price Return-77.78%

Quick Ratio (Annual)1.65x

13-Week Price Return-46.24%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)1.27x

Enterprise Value$3.207

Asset Turnover (TTM)0.95x

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-153.30%

Cash / Share (Annual)$2.57

3-Month Return Std Dev188.90%

Net Income / Employee (TTM)$-2

ROE (Last FY)-215.28%

Net Interest Coverage (Annual)-453.54x

EPS Basic Excl Extra (Annual)$-11.45

Receivables Turnover (TTM)5.02x

Total Debt / Equity (Quarterly)0.32x

EPS Incl Extra (TTM)$-6.36

Receivables Turnover (Annual)7.02x

ROI (TTM)-345.02%

P/S Ratio (TTM)1.00x

Pretax Margin (5Y Avg)-746.56%

Revenue / Share (Annual)$7.47

Tangible BV / Share (Annual)$-6.95

Price vs S&P 500 (52W)-108.50%

Year-to-Date Return-45.65%

5-Day Price Return-9.29%

EPS Normalized (Annual)$-11.45

ROA (5Y Avg)-217.56%

Net Profit Margin (Annual)-153.30%

Month-to-Date Return-7.15%

Cash Flow / Share (TTM)$-7.50

EBITD / Share (Annual)$-9.60

Operating Margin (Annual)-129.18%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-9.12%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-6.36

P/TBV (Quarterly)1.86x

P/B Ratio (Annual)2.18x

Pretax Margin (TTM)-244.49%

Book Value / Share (Annual)$2.73

Price vs S&P 500 (13W)-49.10%

Beta1.07x

Revenue / Share (TTM)$1.56

ROE (TTM)-386.70%

52-Week Low$0.31

Analyst Recommendations

Apr 2024

May 2024

Jun 2024

Jul 2024

4.14

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ENSCEnsysce Biosciences, Inc. Common Stock	1.00x	1.51%	—	—	$0.48
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Ensysce Biosciences is a clinical-stage biotech company developing safer opioid medications using proprietary abuse-resistant and overdose-protection technologies. The company's pipeline includes two drug platforms—the TAAP platform for abuse resistance and the MPAR platform for overdose protection—targeting the severe pain management market while reducing addiction and overdose risk. By addressing a critical unmet need, Ensysce aims to provide healthcare providers with effective pain treatment options that limit potential for drug abuse.